WO2005085861A3 - Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer - Google Patents

Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer Download PDF

Info

Publication number
WO2005085861A3
WO2005085861A3 PCT/EP2005/050897 EP2005050897W WO2005085861A3 WO 2005085861 A3 WO2005085861 A3 WO 2005085861A3 EP 2005050897 W EP2005050897 W EP 2005050897W WO 2005085861 A3 WO2005085861 A3 WO 2005085861A3
Authority
WO
WIPO (PCT)
Prior art keywords
use
nucleic acids
disorders
liver
encoded polypeptides
Prior art date
Application number
PCT/EP2005/050897
Other languages
French (fr)
Other versions
WO2005085861A2 (en
Inventor
Christian Guelly
Heimo Strohmaier
Charles Buck
Kurt Zatloukal
Original Assignee
Oridis Biomed Forschungs Und E
Christian Guelly
Heimo Strohmaier
Charles Buck
Kurt Zatloukal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP04100858 priority Critical
Priority to EP04100858.2 priority
Priority to EP04100857 priority
Priority to EP04100857.4 priority
Application filed by Oridis Biomed Forschungs Und E, Christian Guelly, Heimo Strohmaier, Charles Buck, Kurt Zatloukal filed Critical Oridis Biomed Forschungs Und E
Publication of WO2005085861A2 publication Critical patent/WO2005085861A2/en
Publication of WO2005085861A3 publication Critical patent/WO2005085861A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The invention relates to nucleic acids and to corresponding encoded polypeptides and to their use for the diagnosis, prevention and/or treatment of liver disorders and neoplastic disorders, especially cancer of the liver and other epithelial tissues, benign liver neoplasms such as adenoma and other proliferative liver disorders such as focal nodular hyperplasia (FNH) and cirrhosis. The invention further relates to methods of diagnosing and treating these disorders.
PCT/EP2005/050897 2004-03-03 2005-03-01 Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer WO2005085861A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04100858 2004-03-03
EP04100858.2 2004-03-03
EP04100857 2004-03-03
EP04100857.4 2004-03-03

Publications (2)

Publication Number Publication Date
WO2005085861A2 WO2005085861A2 (en) 2005-09-15
WO2005085861A3 true WO2005085861A3 (en) 2006-02-02

Family

ID=34921312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/050897 WO2005085861A2 (en) 2004-03-03 2005-03-01 Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer

Country Status (1)

Country Link
WO (1) WO2005085861A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8986966B2 (en) 2002-09-27 2015-03-24 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US9174222B2 (en) 2005-04-05 2015-11-03 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
US7842291B1 (en) * 2006-05-22 2010-11-30 Celera Corporation Methods and compositions for diagnosing and treating diseases
EP3399520A1 (en) 2007-09-11 2018-11-07 University of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer
WO2011162558A2 (en) * 2010-06-24 2011-12-29 (주)지노믹트리 Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
MX2013008252A (en) 2011-01-18 2014-04-14 Everist Genomics Inc Prognostic signature for colorectal cancer recurrence.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281898A (en) * 2000-06-27 2001-01-31 国家人类基因组南方研究中心 Human zinc finger protein isomer and its code sequence
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002029103A2 (en) * 2000-10-02 2002-04-11 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
WO2002086076A2 (en) * 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
WO2003100429A2 (en) * 2002-05-23 2003-12-04 Sunnybrook And Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155513A1 (en) * 1999-04-13 2002-10-24 Hsu Daniel K. Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
WO2001059063A2 (en) * 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CN1281898A (en) * 2000-06-27 2001-01-31 国家人类基因组南方研究中心 Human zinc finger protein isomer and its code sequence
WO2002029103A2 (en) * 2000-10-02 2002-04-11 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002086076A2 (en) * 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
WO2003100429A2 (en) * 2002-05-23 2003-12-04 Sunnybrook And Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 11 April 2002 (2002-04-11), XP002333985, retrieved from EMBL Database accession no. ACA54656, 05-JUN-2003 *
DATABASE EMBL [online] 20 January 2003 (2003-01-20), XP002333983, retrieved from EMBL Database accession no. ABZ11419, 20-JAN-2003 *
DATABASE EMBL [online] 23 January 2002 (2002-01-23), XP002333984, retrieved from EMBL Database accession no. ABA11768, 23-JAN-2002 *
MIYASAKA Y ET AL: "ANALYSIS OF DIFFERENTIALLY EXPRESSED GENES IN HUMAN HEPATOCELLULAR CARCINOMA USING SUPPRESSION SUBTRACTIVE HYBRIDIZATION", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 85, no. 2, July 2001 (2001-07-01), pages 228 - 234, XP008013867, ISSN: 0007-0920 *
XIAO Q ET AL: "DUTP PYROPHOSPHATASE AND URACIL-DNA GLYCOSYLASE IN RAT LIVER AND HEPATOMAS", INTERNATIONAL JOURNAL OF BIOCHEMISTRY, TARRYTOWN, NY, US, vol. 24, no. 3, 1992, pages 437 - 445, XP002291123 *
XU X-R ET AL: "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 26, 18 December 2001 (2001-12-18), pages 15089 - 15094, XP002231180, ISSN: 0027-8424 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986966B2 (en) 2002-09-27 2015-03-24 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US9174222B2 (en) 2005-04-05 2015-11-03 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Also Published As

Publication number Publication date
WO2005085861A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2007059108A3 (en) Substituted quinolones and methods of use
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
SG170809A1 (en) Diarylthiohydantoin compounds
MX2008007049A (en) Inhibitors of c-met and uses thereof.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2000028090A3 (en) Diagnostic assay for cancer
WO2001045730A3 (en) Tweak receptor
MX2007002857A (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
WO2005034845A8 (en) Compositions and methods for treatment of cancer
WO2005079844A3 (en) Use for interleukin-33 (il33) and the il-33 receptor complex
WO2004103960A3 (en) Compounds and uses thereof
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
CA2633413A1 (en) Antibodies against tumor-associated antigenic target (tat) polypeptides
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
NZ586780A (en) Antibodies against CD38 for treatment of multiple myeloma
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
WO2007080392A3 (en) Ligands that have binding specificity for vegf and/or egfr and methods of use therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase